drugset / Trial / NCT02539134

TAK-935 Multiple Rising Dose Study in Healthy Participants

NCT02539134

Phase 1 Completed 40 enrolled Takeda
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple rising doses of TAK-935 in healthy participants.

Timeline

Start
2015-09
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Soticlestat Small molecule 100 mg Oral
Subject Soticlestat Small molecule 300 mg Oral
Subject Soticlestat Small molecule 400 mg Oral
Subject Soticlestat Small molecule 600 mg Oral

Indications